Vehicle comparator

DRUG2 trials

Sponsors

Revance Therapeutics, Inc., Palvella Therapeutics, Inc.

Conditions

BCCs in Gorlin Syndrome PatientsCrow's FeetFacial WrinklesLateral Canthal Lines

Phase 2

Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines

CompletedNCT00888914

Revance Therapeutics, Inc.Crow's Feet, Facial Wrinkles, Lateral Canthal Lines

Start: 2008-11-30End: 2009-02-28Updated: 2013-11-19

CODY: A Study Evaluating The Safety And Efficacy Of QTORIN 3.9% Sirolimus Topical Gel For The Prevention Of Basal Cell Carcinomas (BCCs) In Patients With Gorlin Syndrome

CompletedNCT04893486

Palvella Therapeutics, Inc.BCCs in Gorlin Syndrome Patients

Start: 2021-05-06End: 2023-03-13Updated: 2024-08-29